Evidence map›Paper›PMID 38639810›Full record

Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Functional quality of life among newly diagnosed young adult colorectal cancer survivors compared to older adults: results from the ColoCare Study.

Laura B Oswald, Amanda Bloomer, Xiaoyin Li, Esther Jean-Baptiste, Gillian Trujillo, Seth Felder, Brent J Small, Jennifer Ose, Sheetal Hardikar, Ildiko Strehli and 19 more

Registry-linked trialOpen access · greenAbstract readObservational Study
In one paragraph

Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 9 institutions in 2 countries.

Laura B OswaldMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA. Laura.Oswald@Moffitt.org.
Amanda BloomerMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Xiaoyin LiMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Esther Jean-BaptisteMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Gillian TrujilloMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Seth FelderMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Brent J SmallUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jennifer OseHuntsman Cancer Institute, Salt Lake City, UT, USA.
Sheetal HardikarHuntsman Cancer Institute, Salt Lake City, UT, USA.
Ildiko StrehliHuntsman Cancer Institute, Salt Lake City, UT, USA.
Lyen C HuangHuntsman Cancer Institute, Salt Lake City, UT, USA.
Kathi MooneyHuntsman Cancer Institute, Salt Lake City, UT, USA.
Matthew G MutchUniversity of Applied Sciences and Arts, Hanover, Germany.
Dante ChaoWashington University School of Medicine, St. Louis, MO, USA.
Stacey A CohenFred Hutchinson Cancer Center, Seattle, WA, USA.
Meghana KarchiUniversity of Tennessee Health Science Center, Memphis, TN, USA.
Elizabeth H WoodUniversity of Tennessee Health Science Center, Memphis, TN, USA.
Victoria DamerellHeidelberg University Hospital, Heidelberg, Germany.
Nicole C LoroñaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jun GongSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Adetunji T ToriolaWashington University School of Medicine, St. Louis, MO, USA.
Christopher I LiFred Hutchinson Cancer Center, Seattle, WA, USA.
David ShibataUniversity of Tennessee Health Science Center, Memphis, TN, USA.
Martin SchneiderHeidelberg University Hospital, Heidelberg, Germany.
Biljana GigicHeidelberg University Hospital, Heidelberg, Germany.
Jane C FigueiredoSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Heather S L JimMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Cornelia M UlrichHuntsman Cancer Institute, Salt Lake City, UT, USA.
Erin M SiegelMoffitt Cancer Center, 12902 USF Magnolia Drive, MRC-HOB, Tampa, FL, 33612, USA.
Moffitt Cancer Center · USHuntsman Cancer Institute · USCedars-Sinai Medical Center · USUniversity Hospital Heidelberg · DEUniversity of Tennessee Health Science Center · USFred Hutch Cancer Center · USUniversity of Utah · USWashington University in St. Louis · USUniversity of North Carolina at Chapel Hill · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and BehaviorsR01NR018762 · NINR · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., JIM, HEATHER S.L. · 2020 to 2024
$3.4M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancerR01AG083580 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheetal Hardikar · 2024 to 2026
$2.3M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA254108NCI NIH HHS U01 CA206110NIA NIH HHS R01 AG083580NINR NIH HHS R01 NR018762
6 · The paper itself

Abstract

purposeColorectal cancer (CRC) incidence and mortality are increasing among young adults (YAs) aged 18-39. This study compared quality of life (QOL) between YA and older adult CRC survivors in the ColoCare Study.

methodsParticipants were grouped by age (years) as follows: 18-39 (YA), 40-49, 50-64, and 65 + . Functional QOL (physical, social, role, emotional, cognitive) and global QOL were assessed with the EORTC-QLQ-C30 at enrollment, 3, 6, and 12 months. Average scores were compared between groups over time using longitudinal mixed-effect modeling. Proportions with clinically meaningful QOL impairment were calculated using age-relevant thresholds and compared between groups over time using logistic regression with mixed effects.

resultsParticipants (N = 1590) were n = 81 YAs, n = 196 aged 40-49, n = 627 aged 50-64, and n = 686 aged 65 + . Average physical function was better among YAs than participants aged 50-64 (p = 0.010) and 65 + (p < 0.001), and average social function was worse among YAs than aged 65 + (p = 0.046). Relative to YAs, all age groups were less likely to report clinically meaningful social dysfunction (aged 40-49 OR = 0.13, 95%CI = 0.06-0.29; aged 50-64 OR = 0.10, 95%CI = 0.05-0.21; aged 65 + OR = 0.07, 95%CI = 0.04-0.15) and role dysfunction (aged 40-49 OR = 0.36, 95%CI = 0.18-0.75; aged 50-64 OR = 0.41, 95%CI = 0.22-0.78; aged 65 + OR = 0.32, 95%CI = 0.17-0.61). Participants aged 40-49 were also less likely to report physical dysfunction (OR = 0.42, 95%CI = 0.19-0.93).

conclusionYA CRC survivors reported better physical and worse social function compared to older CRC survivors, and YA CRC survivors were more likely to report clinically meaningful social, role, and physical disfunction. Future work should further investigate QOL using age-relevant benchmarks to inform best practices for CRC survivorship care.

trial registrationNCT02328677, registered December 2014.

Indexed as

Cancer SurvivorsColorectal NeoplasmsAdolescentAdultAgedEmotionsHumansMiddle AgedQuality of LifeSurvivorsYoung AdultCancer survivorsColorectal cancerPatient-reported outcomesQuality of lifeYoung adult

Identifiers

PMID38639810
PMCPMC11103673
OpenAlexW4394962417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.